CAPLYTA Drug Patent Profile

When do Caplyta patents expire, and what generic alternatives are available?

Caplyta is a drug marketed by Intra-cellular and is included in one NDA. There are twenty-five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-eight patent family members in twenty countries.

The generic ingredient in CAPLYTA is lumateperone tosylate. One supplier is listed for this compound. Additional details are available on the lumateperone tosylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Caplyta

Caplyta was eligible for patent challenges on December 20, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 10, 2040. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (lumateperone tosylate), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for CAPLYTA

International Patents:	178
US Patents:	25
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	40
Clinical Trials:	3
Drug Prices:	Drug price information for CAPLYTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CAPLYTA
What excipients (inactive ingredients) are in CAPLYTA?	CAPLYTA excipients list
DailyMed Link:	CAPLYTA at DailyMed

See drug prices for CAPLYTA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CAPLYTA

Constraining patent/regulatory exclusivity:

12,410,195

NDA:

209500

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CAPLYTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Massachusetts, Worcester	Phase 4
Intra-Cellular Therapies, Inc.	Phase 4
University of New Mexico	Phase 4

See all CAPLYTA clinical trials

Pharmacology for CAPLYTA

Drug Class

Atypical Antipsychotic

Paragraph IV (Patent) Challenges for CAPLYTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CAPLYTA	Capsules	lumateperone tosylate	42 mg	209500	7	2023-12-20

US Patents and Regulatory Information for CAPLYTA

CAPLYTA is protected by forty-one US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 12,410,195.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No	11,690,842		Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-002	Apr 22, 2022		RX	Yes	No
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No	10,464,938		Y
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-003	Apr 22, 2022		RX	Yes	No	11,026,951
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019		RX	Yes	Yes	8,648,077		Y	Y

Expired US Patents for CAPLYTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019	7,183,282
Intra-cellular	CAPLYTA	lumateperone tosylate	CAPSULE;ORAL	209500-001	Dec 20, 2019	RE39680

International Patents for CAPLYTA

When does loss-of-exclusivity occur for CAPLYTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

European Patent Office

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CAPLYTA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2009251816	Methods and compositions for sleep disorders and other disorders
Australia	2015218433	METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS
Canada	2725342	GAMMA-CARBOLINES FUSIONNEES A HETEROCYCLE SUBSTITUE POUR LES TROUBLES DU SOMMEIL ET AUTRES TROUBLES (SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES FOR SLEEP DISORDERS AND OTHER DISORDERS)
China	102105059
China	105168219	用于睡眠障碍和其他疾病的方法和组合物 (Methods and compositions for sleep disorders and other disorders)

Last updated: June 3, 2026

CAPLYTA (caplyta) market dynamics and financial trajectory: revenue drivers, share movement, exclusivity, and generic/biosimilar risk

CAPLYTA (lumateperone; Janssen) has moved from early uptake to a more mature launch phase dominated by formulary penetration in mood disorders, prescriber concentration in psychiatry, and competitive pressure from branded and long-established antipsychotics plus newer schizophrenia and bipolar agents. Financial trajectory is shaped by (1) net price and payer mix, (2) durability of exclusivity protection tied to FDA listed exclusivities and patent estate coverage, and (3) timing and threat level of generic entry for lumateperone tablets, plus any switching risk from competing atypical antipsychotics used across schizophrenia and bipolar depression.

The market is segmented primarily by: schizophrenia (adjunctive antipsychotic use in clinical practice) and bipolar depression (type 1 and/or type 2 indications depending on label and guideline adoption). Within payer dynamics, managed care channels and specialty pharmacy distribution determine revenue outcomes more than pure unit demand. The key financial question for CAPLYTA is not whether utilization grows, but whether net revenue per treated patient holds while competition compresses gross-to-net.

How has CAPLYTA (lumateperone) revenue performed and what drives the financial trajectory?

Short answer: CAPLYTA’s revenue trajectory tracks net price and payer access rather than only prescription counts, with incremental demand supported by guideline alignment in bipolar depression and schizophrenia maintenance where clinicians accept lumateperone’s side effect profile and dosing convenience.

Key revenue drivers that typically govern CAPLYTA’s P&L

• Gross-to-net compression: Branded psychiatric drugs often face contracting dynamics including rebates, patient assistance, and formulary tier placement. Financial trajectory usually bends when payer mix shifts toward lower net pricing tiers.
• Payer access and utilization management: Prior authorization, step therapy policies, and restricted formularies influence patient starts and persistence.
• Indication mix: Revenue is sensitive to which segment outgrows the other. Bipolar depression often has tighter formulary control because payers view treatment options as substitutable within atypical classes.
• Prescriber and clinic adoption: Uptake in psychiatry tends to concentrate in certain geographies and systems, so hospital system wins and IDNs can swing quarterly volume.

What to watch in quarterly reporting

For Janssen’s CAPLYTA performance, the most decision-relevant metrics are:

• U.S. prescriptions and TRx trends (proxy for unit demand)
• U.S. net sales by indication (if disclosed)
• Channel mix (specialty pharmacy vs institutional)
• Inventory behavior (avoid false signals from stocking)

Timing risk: can volume growth offset net price erosion?

In mature branded CNS franchises, net revenue often declines if volume growth fails to keep pace with gross-to-net deterioration. CAPLYTA’s financial trajectory depends on whether it retains a premium position (distinct tolerability attributes) after competitor contracting pressures.

---

What patents protect CAPLYTA (lumateperone) and how strong is the patent estate for generic risk?

Short answer: Lumateperone’s generic threat is constrained by the combination of patent coverage on the active ingredient, compositions (including crystalline or polymorphic forms where applicable), formulation and dosing forms, and method-of-use protections tied to labeled indications. The practical risk is defined by how many enforceable Orange Book-listed patents map to each proposed generic filing.

Typical CAPLYTA patent estate elements (what matters for litigation and launch)

• Active ingredient / composition-of-matter patents
• Formulation patents (tablet compositions, excipient systems, release characteristics)
• Solid-state or polymorph patents (if listed)
• Method-of-use patents aligned to bipolar depression and schizophrenia endpoints
• Manufacturing process patents (where listed)

How patent strength translates into launch leverage

Generic challenge leverage increases if:

• A court finds claims invalid or not infringed.
• The Orange Book list is sparse or contains weak-to-moderate claims.
• Settlement allows “at-risk” or “design-around” earlier entry.

Launch leverage decreases if:

• There is a layered set of enforceable patents with staggered expirations.
• Multiple asserted patents cover each generic product configuration.

---

When does CAPLYTA lose exclusivity in the U.S., including FDA exclusivity and patent expiration?

Short answer: CAPLYTA’s path to generic entry depends on the intersection of (1) patent expiration or earlier court outcomes and (2) any statutory or regulatory exclusivity periods that delay approval or marketing for generic products.

Exclusivity components that typically delay competition

• Orphan or other statutory exclusivities (if applicable; only relevant if the drug qualifies)
• Hatch-Waxman patent term and listed patent expiry
• Data exclusivity tied to the new chemical entity or new indications

Why “loss of exclusivity” differs from “first generic approval”

Even if a relevant listed patent expires, marketing can remain blocked by:

• unexpired patents not yet resolved
• remaining regulatory exclusivity protections
• negotiated settlement terms that can delay launch

---

What generic entry risks exist for CAPLYTA tablets, and what is the Paragraph IV landscape?

Short answer: Generic entry for lumateperone tablets is a classic Hatch-Waxman profile: risk spikes around listed patent expiry windows and any Paragraph IV certifications that trigger litigation. The real market impact depends on whether challengers win an injunction-free path to launch or are blocked by court action or settlements.

Paragraph IV risk mechanics that drive market share

• Certification strategy: Generics target the most vulnerable listed patents for invalidity/non-infringement arguments.
• Injunction outcomes: If the court stays approval or issues an injunction, CAPLYTA retains market position.
• Settlement timing: Settlements can “buy time” and prevent immediate at-launch price collapse.

Market impact if a generic launches

• Price compression: Branded-to-generic discounts typically accelerate after launch.
• Formulary switching: Payers switch preferred agents if interchangeability and rebate economics favor generics.
• Persistence and substitution: CNS patients are slower to switch if prescribers worry about stability and side effects, but managed care can still drive conversion over time.

---

What is the Orange Book status of CAPLYTA (lumateperone) and how many listed patents block generics?

Short answer: The practical exclusivity barrier is the count, scope, and expiration timing of FDA Orange Book-listed patents that are relevant to each generic certification. More listed patents, shorter overlap, and earlier expiration of the weakest claims all affect how soon a challenger can obtain a launch-ready pathway.

How to interpret Orange Book lists for CAPLYTA

• Number of patents by category: composition-of-matter, formulation, and method-of-use.
• Earliest expiry date vs. “marketing start” constraints: not all patents have equal leverage.
• Claim coverage breadth: narrower claims may be easier to design around, broad claims harder.

What matters for investors and licensors

The decision is usually not “how many patents exist,” but:

• whether the patents map to the generic product’s structure and use
• whether courts are likely to invalidate or narrow claims

---

Which companies are challenging CAPLYTA and what patent litigation affects the launch timeline?

Short answer: Generic challengers for CAPLYTA would be expected to target lumateperone tablet patent listings with Paragraph IV certifications. Litigation outcome and settlement terms determine launch timing and whether CAPLYTA’s revenue experiences a full price-collapse cycle or a delayed/partial erosion.

Litigation factors that move revenue

• Court schedule: faster decisions reduce time for generic preparations.
• Injunction scope: blocks approval at the FDA level or delays marketing.
• Settlement terms: determine “first authorized launch” dates and any non-infringement covenants.

Commercial consequence

A successful generic launch often triggers:

• a step-change in market share away from the brand
• a rapid decline in net price as contracting changes

---

How does CAPLYTA compare with competing atypical antipsychotics for schizophrenia and bipolar depression?

Short answer: CAPLYTA competes in overlapping clinician decision sets where tolerability, metabolic risk, sedation profile, and patient adherence are key. Revenue outcome often correlates with how often prescribers perceive lumateperone as a better-tolerated alternative within the antipsychotic class.

Competitive set by use case (treatment switching risk)

• Bipolar depression competitors: branded and off-patent agents used for acute bipolar depression and relapse prevention.
• Schizophrenia competitors: long-established atypical antipsychotics with entrenched payer coverage and clinician familiarity.

How competition changes CAPLYTA’s economics

• Net price pressure: competing contracts can force CAPLYTA down in tiers.
• Copay and patient support dynamics: other brands’ assistance programs shift patient behavior at the margin.
• Formulary placement: a single payer wins or losses can materially alter quarterly revenue.

---

What formulations are protected for CAPLYTA and what manufacturing/IP barriers block generic design-arounds?

Short answer: The most effective generic barriers usually come from formulation and solid-state protections that limit easy product equivalence. Manufacturing process patents can also raise friction for generic suppliers trying to reproduce the brand’s critical quality attributes.

Formulation IP that affects generic feasibility

• Tablet composition and excipient selection
• Release characteristics and dissolution behavior
• Solid-state form or polymorph control
• Stability and manufacturing method requirements

Design-around pathways generics pursue

• changing solid-state form (if not protected)
• changing excipient matrix
• changing manufacturing method while meeting bioequivalence

---

How does CAPLYTA’s patent and exclusivity position affect biosimilar-style risk (and why it is different)?

Short answer: Biosimilar risk is not the main framework for CAPLYTA because lumateperone is a small molecule. The generic erosion mechanism is Hatch-Waxman small-molecule generic entry, not biosimilar exclusivity.

What replaces biosimilar risk for CAPLYTA

• Paragraph IV small-molecule challenges
• patent expiration and Orange Book blocking
• settlements and authorized generics

---

What commercialization and contracting strategies influence CAPLYTA net sales most?

Short answer: For psychiatric brands, contracting outcomes, specialty pharmacy economics, and payer access rules drive net sales more than marginal incremental prescriptions.

Key levers

• Formulary strategy: secure tier placement with rebate schedules pegged to volume
• Prior authorization protocols: compliance and clinical criteria shape start rates
• Specialty distribution: timely patient starts depend on delivery channel effectiveness
• Patient support: copay and assistance programs reduce abandonment and improve adherence

---

What generic launch scenarios could impact CAPLYTA’s revenue in the first 12 to 24 months?

Short answer: Revenue impact depends on whether a generic enters at full volume immediately, enters after a delayed settlement, or faces multiple injunction hurdles that produce a staggered “partial erosion” rather than a steep decline.

Scenario map

1. Full launch with injunction-free approval
   • rapid market share shift
   • sharp net price compression
2. Delayed launch post-settlement
   • CAPLYTA retains market position longer
   • revenue erosion begins later
3. At-risk launch followed by adverse litigation
   • potential brand clawback via market withdrawal
   • revenue volatility and contracting uncertainty

What determines which scenario occurs

• strength of asserted claims
• settlement breadth and timing
• speed of generic ramp-up and payer switching

---

Key Takeaways

• CAPLYTA’s financial trajectory is primarily driven by net price and payer access in schizophrenia and bipolar depression, not just unit growth.
• The generic threat hinges on the Orange Book-listed patent portfolio mapping to lumateperone tablet product configuration and labeled use.
• The timing of revenue erosion is determined by patent expiry and Paragraph IV litigation/settlement outcomes, producing either full erosion at launch or delayed/partial erosion.
• Competitive dynamics in atypical antipsychotics shape contract outcomes and formulary placement, influencing CAPLYTA’s net sales stability through gross-to-net compression.

---

FAQs

1. How do payer formulary changes typically affect CAPLYTA net sales after a new competitor enters the class?
2. What is the revenue risk difference between an at-launch Paragraph IV generic and a delayed settlement entry?
3. Which patent categories (composition, formulation, method-of-use) most often control generic launch timelines for small-molecule CNS drugs like lumateperone?
4. How does long-term persistence in bipolar depression and schizophrenia influence branded antipsychotic revenue stability during early generic ramp periods?
5. What contracting structures (rebates, PA requirements, specialty pharmacy economics) usually determine gross-to-net outcomes for branded CNS therapies?

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. U.S. Food and Drug Administration. Drug Trials Snapshots. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots
3. FDA. Hatch-Waxman Act and exclusivity basics (FDA educational materials). https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-act-and-accelerated-approval-implementation
4. Bloomberg Law / patent databases (used for patent estate mapping in pharmaceutical analyses). (Access varies by subscription)

DrugChatter Q&A for CAPLYTA

Caplyta patent expiration?
Caplyta fda approval date?
Caplyta financial assistance?
Is there a generic caplyta?
Generic caplyta availability?